Our mission is to provide new products and services to society that mean a breakthrough in the prevention and personalized treatment of different pathologies
Biomeb is a health technology company promoting metabolomics for precision medicine as well as research in other fields of life science, providing new products and services to society that means a breakthrough in the prevention, diagnosis and personalized treatment of different pathologies.
Our metabolomics approach is a competent technology for assessing one’s metabolic state that can be used to hand in tips to achieve a healthier lifestyle.
Currently we collaborate on different research projects together with entities and professionals for the development of new products and services.
Multifunctional Dietary fibre to tackle metabolic syndrome. Fibracep® is a new patented bioactive product based on fibres extracted from natural sources, clinically tested.
In several aleatorized, placebo-controlled clinical trials, Fibracep® is effective to modulate the risk of metabolic syndrome development, by acting on several of its components.
Well B is conceived as an emerging approach for disease prevention and lifestyle management that considers each person as a whole using metabolomics, anthropometric, biochemical, environmental and lifestyle data to assess cardiovascular health in a personalized manner.
Thus, Well B provides precise personal nutritional recommendations based on the metabolic profile for improved health through personalized nutrition.
Our commitment to research, development and Innovation, provided by a high level scientific and management team with years of experience, has given rise to a portfolio of new projects that will guarantee the release to the market of new products and services in the short/medium term.
Biomeb offers basic equipment from our biomedical laboratory, as well as high-performance equipment such as different chromatographs (liquid and gases) coupled to mass spectrometers (QTOF, TQD). This equipment has allowed the development of innovative technologies such as metabolomics that has been applied to the health field.
Biomeb’s scientific team is part of the NUTREN research group from the University of Lleida and the Biomedical Research Institute of Lleida (IRBLLEIDA). It has more than 200 publications of international impact in the areas of development of our products.
Biomeb’s R&D&I strategy for the upcoming years will be our investment in the development of new products and services using metabolomics applied to the health and agri-food sectors and the design and development of new foods together with the discovery of new biomarkers.
Metabolomics at your service
We offer a complete metabolomics service in the following areas
Support the discovery, development and validation of biomarkers.
Discovery and development of customizable bioactive therapeutic targets and compounds.
Advancing knowledge and discovery of new biomarkers.
Characterization of bioactive compounds and bioavailability.